Cumberland Pharma

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which engages in the acquisition, development, and commercialization of prescription products. Its product include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, and RediTrex. The company was founded by A. J. Kazimi on January 6, 1999 and is headquartered in Nashville, TN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Cumberland Pharma reports steady Q1 performance amidst sales challenges

Cumberland Pharma's Q1 2024 performance showcased resilience in the face of sales challenges, with a strategic emphasis on FDA-approved brands. The company's dedication to innovation and patient care underpins its growth trajectory, despite hurdles posed by insurance deductibles.

Cumberland Pharma reports revenue growth but faces profitability challenges

Cumberland Pharmaceuticals demonstrated revenue growth potential but grappled with profitability challenges in Q2 2024. The company's focus on innovation, market expansion, and patient care underscores a commitment to long-term success. Addressing cost management, profitability, and leveraging growth opportunities will be crucial for Cumberland's future.

Cumberland Pharma reports resilient Q3 performance amidst operational challenges

Cumberland Pharma's Q3 2024 performance was driven by FDA-approved brands despite challenges.
The company showcased improved financials with a focus on operational efficiency and growth opportunities.
While facing challenges like product returns and expenses, Cumberland maintains a strong financial position.
Strategic initiatives and research efforts position Cumberland for future growth and profitability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Cumberland Pharmaceuticals, Inc. is a specialty pharmaceutical company, which focuses on the acquisition, development, and commercialization of branded prescription pharmaceutical products. Its products include Acetadote, Caldolor, Kristalose, Omeclamox, Vaprisol, Vibativ, Sancuso, Boxaban, Vasculan. Dyscorban, and RediTrex. The company was founded by A. J. Kazimi on January 7, 1999 and is headquartered in Nashville, TN.

Cumberland (CPIX) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Here is Why Growth Investors Should Buy Cumberland (CPIX) Now

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q2 2019 Earnings Conference Call August 14, 2019 4:30 PM ET

Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q2 2019 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 42.86% and -8.01%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q2 Earnings Beat Estimates

Cumberland (CPIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Cumberland Pharmaceuticals (CPIX) Earnings Expected to Grow: What to Know Ahead of Q2 Release

In the latest trading session, Cumberland Pharmaceuticals (CPIX) closed at $6.35, marking a +0.79% move from the previous day.

Cumberland Pharmaceuticals (CPIX) Gains As Market Dips: What You Should Know

Is  (CPIX) Outperforming Other Medical Stocks This Year?

Has Cumberland Pharmaceuticals (CPIX) Outpaced Other Medical Stocks This Year?

Cumberland (CPIX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Cumberland (CPIX) Upgraded to Strong Buy: Here's What You Should Know

Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX) Q1 2019 Results Earnings Conference Call May 14, 2019 4:30 PM ET

Cumberland Pharmaceuticals Inc. (CPIX) CEO A.J. Kazimi on Q1 2019 Results - Earnings Call Transcript

Cumberland (CPIX) delivered earnings and revenue surprises of 200.00% and 11.24%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Cumberland Pharmaceuticals (CPIX) Q1 Earnings and Revenues Beat Estimates

Cumberland (CPIX) will provide updates on pipeline candidates with the release of its first-quarter 2019 results.

What's in Cards for Cumberland (CPIX) This Earnings Season?

News for Cumberland Pharma Stock (CPIX)